Beyond the Guidelines for CMV: Clinical Perspectives on Challenging Cases Post-Transplant: A Clinical Forum
Released On
December 02, 2024
Expires On
December 01, 2025
Media Type
Internet
Completion Time
90 minutes
Specialty
Infectious Disease, Nephrology, Pharmacy, Surgery
Topic(s)
Pharmacology, Surgery
Provider Statement
Provided by RMEI Medical Education, LLC.
Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.
Credit Available
- Physicians — maximum of 1.5 AMA PRA Category 1 Credit(s)™
- Pharmacists — 1.5 Contact Hours
- Nurses — 1.5 Nursing Contact Hours
All other healthcare professionals completing this course will be issued a statement of participation.
Target Audience
Infectious disease, transplantation, internal medicine, and nephrology clinicians
Program Overview
Cytomegalovirus (CMV) is a prevalent and potentially life-threatening viral infection in transplant recipients. CMV management in this high-risk population continues to evolve with updated guidelines and newer, less toxic antiviral therapy.
During this activity, faculty will discuss state-of-the-art strategies for preventing and treating CMV in transplant patients, sharing practical insights from challenging cases encountered in their clinical practice.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Apply treatment strategies for cytomegalovirus (CMV) infection in transplant recipients
- Identify refractory or drug-resistant CMV in transplant recipients in the post-transplant setting
- Integrate new antiviral therapies into management regimens for transplant recipients, including those who develop refractory or drug-resistant CMV
Faculty
Emily A. Blumberg, MD
Specialist, Transplant Infectious Diseases
Director, Transplant Infectious Diseases
Program Director, Infectious Diseases Fellowship
Perelman School of Medicine at the University of Pennsylvania
Philadelphia, PA
Marcus R. Pereira, MD, MPH, FAST
Associate Professor, Medicine
Medical Director, Transplant Infectious Diseases Program
Columbia University Irving Medical Center
NewYork-Presbyterian Hospital
New York, NY
Joint Accreditation Statement
In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Continuing Pharmacy Education
RMEI Medical Education, LLC designates this continuing education activity for 1.5 contact hour(s) (0.15 CEUs) of the
Accreditation Council for Pharmacy Education.
(Universal Activity Number — JA4008290-0000-24-008-H01-P)
Type of Activity: Knowledge
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.5 contact hours.
Disclosures of Financial Relationships
RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.
Faculty
Emily A. Blumberg, MD, has relevant financial relationship(s) with Merck, Scynexis, Takeda (Grant Research Support).
Marcus R. Pereira, MD, MPH, FAST, has relevant financial relationship(s) with AstraZeneca, Takeda (Speaker); Synklino (Consultant).
All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.
Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.
Instructions for Receiving Credit
To receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at [email protected].
Users must:
- Read the learning objectives and faculty disclosures
- Participate in the activity
- Complete the activity evaluation
There is no fee to participate.
For Pharmacists: You must provide your NABP eProfile ID and Date of Birth (MMDD format) in order to receive credit for the activity.
Course Viewing Requirements
Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
If you have questions about this activity, please contact RMEI at [email protected].